Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 27 September 1996:
Vol. 273. no. 5283, pp. 1798 - 0
DOI: 10.1126/science.273.5283.1798
Prev | Table of Contents | Next

Research News

Jon Cohen

When Stephen O'Brien quickly put together a powerful analysis of the link between genetic mutations and susceptibility to HIV infection, he set off a flap among some colleagues and competitors. O'Brien analyzed DNA from cell lines he had established from large numbers of blood samples provided by other investigators, some of whom say they were not aware of the study until a draft manuscript was circulated. Others complained that his ready access to the cell lines gave him an unfair advantage. O'Brien, who included as co-authors those who provided samples, says the work was covered by collaborative agreements. The flap highlights an issue that is becoming increasingly important in biomedical research: Who should control research on scarce samples?

Read the Full Text

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)